查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1588573

全球综合器官支持疗法市场 - 2024-2031

Global Integrated Organ Support Therapies Market - 2024-2031
出版日期: | 出版商: DataM Intelligence | 英文 179 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

概述

全球综合器官支持疗法市场在2023年达到39.1亿美元，预计到2031年将达到59.6亿美元，在2024-2031年预测期间复合年增长率为5.5%。

综合器官支持疗法是一套多学科、协调一致的医疗干预措施和设备，旨在维持、支持或暂时替代危重患者一个或多个衰竭器官的功能。这些疗法主要用于重症监护室和急诊护理机构，这些机构中的患者患有严重的健康状况，包括多重器官衰竭、败血症、呼吸窘迫、急性肾损伤或肝衰竭等。

综合器官支持疗法旨在维持器官功能，以防止不可逆转的损伤并稳定患者的病情，同时治疗根本原因或使身体痊癒。例如，根据organdonor.gov的数据，全国移植等待名单上有103,223名男性、女性和儿童，在这种情况下，这些综合器官支持疗法可能会有所帮助，这进一步有助于推动市场成长。

市场动态：

司机

慢性和急性器官衰竭的盛行率上升

慢性和急性器官衰竭的盛行率不断上升，与对能够同时管理或替代多个器官功能的综合器官支持疗法的需求不断增长直接相关，因为这些情况显着增加了对生命支持干预措施和多器官管理的需求。慢性和急性器官衰竭都会损害身体执行基本功能的能力，因此需要整合的器官支持设备和疗法来暂时替代或支持这些衰竭的器官。

例如，根据美国国立卫生研究院 (NIH) 进行的研究，该研究显示新器官衰竭的发生率为 1,342/1,00,000 人年，在所有急诊接触者中的盛行率为 5.2%。器官衰竭患者的一年全因死亡率为 29.8%。随着器官衰竭的增加，对综合器官支持疗法的需求预计将持续成长。

限制

与器官支持疗法和设备相关的风险和併发症、器官支持设备和疗法的高成本、复杂的监管审批流程、高维护和操作要求以及设备的便携性和移动性有限等因素预计将阻碍综合器官支持疗法市场。

虽然这些疗法对于治疗多重器官衰竭患者至关重要，但相关的风险、併发症和潜在副作用可能会影响其采用和疗效。使用此类设备的复杂性也给医疗保健系统带来了额外的负担，这可能会阻碍市场的成长。

例如，与器官支持疗法相关的最严重的併发症之一是感染风险增加，尤其是体外膜氧合（ECMO）和连续肾臟替代疗法（CRRT）等侵入性设备。许多器官支持装置，特别是 ECMO 和 CRRT，涉及体外循环血液，这进一步带来了血栓形成或出血的重大风险。这些风险可能会阻碍市场的成长。

目录

第 1 章：方法与范围

第 2 章：定义与概述

第 3 章：执行摘要

第 4 章：动力学

  • 影响因素
    • 司机
      • 慢性和急性器官衰竭的盛行率上升
      • 器官支持装置的技术进步
    • 限制
      • 与器官支持疗法和设备相关的风险和併发症
    • 机会
    • 影响分析

第 5 章：产业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 专利分析
  • 监管分析
  • SWOT分析
  • 未满足的需求

第 6 章：按治疗类型

  • 体外膜氧合（ECMO）
    • 静脉-静脉 (VV)
    • 静脉-动脉 (VA)
    • 动静脉 (AV)
  • 连续性肾臟替代疗法（CRRT）
    • 连续性静脉静脉血液滤过（CVVH）
    • 连续性静脉-静脉血液透析（CVVHD）
    • 连续性静脉静脉血液透析滤过（CVVHDF）
    • 慢速连续超滤 (SCUF)
  • 体外二氧化碳去除 (ECCO2R)
  • 肝臟支援系统
    • 分子吸附剂循环系统
    • 生物人工肝支持
  • 心臟辅助装置
    • 主动脉内球囊反搏器
    • 心室辅助装置
    • 人工器官总数

第 7 章：按形态

  • 便携式/便携式设备
  • 床边设备
  • 植入式装置

第 8 章：按申请

  • 呼吸衰竭
  • 心臟衰竭
  • 肝衰竭
  • 肾衰竭
  • 多重器官衰竭

第 9 章：依病患类型

  • 成人患者
  • 儿科患者
  • 新生儿患者

第 10 章：最终用户

  • 医院
  • 专科诊所
  • 门诊手术中心
  • 加护病房 (ICU)

第 11 章：按地区

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第 12 章：竞争格局

  • 竞争场景
  • 市场定位/份额分析
  • 併购分析

第 13 章：公司简介

  • Emulate, Inc.
    • 公司概况
    • 产品组合和描述
    • 财务概览
    • 主要进展
  • Baxter International Inc.
  • Fresenius Medical Care AG
  • Getinge AB
  • LivaNova, Inc.
  • Asahi Kasei Corporation
  • ADVITOS GmbH
  • NIHON KOHDEN CORPORATION
  • Vapotherm
  • Fisher & Paykel Healthcare Limited

第 14 章：附录

简介目录
Product Code: OT8718

Overview

The global integrated organ support therapies market reached US$ 3.91 billion in 2023 and is expected to reach US$ 5.96 billion by 2031, growing at a CAGR of 5.5% during the forecast period 2024-2031.

Integrated organ support therapies are a multidisciplinary and coordinated set of medical interventions and devices that are designed to sustain, support or temporarily replace the functions of one or multiple failing organs in critically ill patients. These therapies are primarily used in intensive care units and acute care settings where patients suffer from severe health conditions, including multi-organ failure, sepsis, respiratory distress, acute kidney injury or liver failure and among others.

Integrated organ support therapies aim to maintain organ functions to prevent irreversible damage and stabilize patients while underlying causes are treated or the body heals. For instance, according to organdonor.gov, 103,223 men, women and children are on the national transplant waiting list, in such cases, these integrated organ support therapies may be helpful, which further helps to boost the market growth.

Market Dynamics: Drivers

Rising prevalence of chronic and acute organ failures

The increasing prevalence of both chronic and acute organ failures directly correlates with the rising demand for integrated organ support therapies that can manage or replace the function of multiple organs simultaneously, as these conditions significantly increase the need for life-support interventions and multi-organ management. Both chronic and acute organ failures impair the body's ability to perform essential functions, necessitating integrated organ support devices and therapies that can temporarily replace or support these failing organs.

For instance, according to the study conducted by the National Institute of Health (NIH), the study revealed the incidence of new organ failure at 1,342/1,00,000 person-years and a prevalence of 5.2% of all emergency department contacts. One-year all-cause mortality was 29.8% among organ failure patients. As organ failures are on the rise, the demand for integrated organ support therapies is expected to grow continuously.

Restraints

Factors such as risks and complications associated with organ support therapies and devices, high costs of organ support devices and therapies, complex regulatory approval processes, high maintenance and operational requirements and limited portability and mobility of devices are expected to hamper the integrated organ support therapies market.

While these therapies are essential for managing patients with multi-organ failure, the associated risks, complications and potential side effects can affect their adoption and efficacy. The complexity of using such devices also places an additional burden on healthcare systems, which can hamper the growth of the market.

For instance, one of the most serious complications associated with organ support therapies is the increased risk of infection, especially with invasive devices like extracorporeal membrane oxygenation (ECMO) and continuous renal replacement therapy (CRRT). Many organ support devices, particularly ECMO and CRRT, involve circulating blood outside the body, this further poses a significant risk of blood clot formation or bleeding. These risks may hamper the growth of the market.

Segment Analysis

The global integrated organ support therapies market is segmented based on therapy type, modality, application, patient type, end-user and region.

The multi-organ failure from the application segment accounted for approximately XX% of the global integrated organ support therapies market share

The multi-organ failure segment is expected to hold the largest market share over the forecast period. Integrated organ support therapies are critical in the management of multi-organ failure, a condition where two or more organs fail simultaneously, often resulting from severe infections, trauma or underlying chronic conditions. These therapies provide life-sustaining support to failing organs, enabling doctors to stabilize the patient while the underlying causes are treated or recovery occurs.

For instance, according to a study conducted by ScienceDirect, in surgical critical care units, 50-80% of all deaths are due to multiple organ failure (MOF). The origin of MOF is still not well understood, therapy is still mainly supportive and the death rate (30-70% in most series) has not significantly decreased even though the syndrome was first identified more than 20 years ago. Thus, the rising burden of MOF further increases the demand for integrated organ support therapies.

Geographical Analysis

North America accounted for approximately XX% of the global integrated organ support therapies market share

North America region is expected to hold the largest market share over the forecast period owing to the rising prevalence of chronic diseases and critical illnesses and high healthcare expenditure. Chronic diseases and critical illnesses are the leading causes of organ failure in the region especially in the United States, directly driving the need for integrated organ support therapies. Conditions such as cardiovascular diseases, chronic kidney disease (CKD), diabetes and respiratory diseases significantly increase the incidence of multi-organ failure, where organ support therapies become crucial for patient survival.

For instance, according to the American Kidney Fund Organization, about 808,000 Americans are living with kidney failure. According to the CDC, the US Department of Health and Human Services estimated that 129 million Americans suffer from at least one severe chronic disease.

The U.S. healthcare system is the largest spender on healthcare globally. For instance, according to the U.S. Centers for Medicare & Medicaid Services, US healthcare spending grew 4.1 percent in 2022, reaching $4.5 trillion or $13,493 per person. As a share of the nation's GDP, health spending accounted for 17.3%, which includes significant expenditures on critical care technologies, including ECMO, CRRT and others.

Market Segmentation

By Therapy Type

  • Extracorporeal Membrane Oxygenation (ECMO)
    • Veno-Venous (VV)
    • Veno-Arterial (VA)
    • Arterio-Venous (AV)
  • Continuous Renal Replacement Therapy (CRRT)
    • Continuous Venovenous Hemofiltration (CVVH)
    • Continuous Venovenous Hemodialysis (CVVHD)
    • Continuous Venovenous Hemodiafiltration (CVVHDF)
    • Slow Continuous Ultrafiltration (SCUF)
  • Extracorporeal CO2 Removal (ECCO2R)
  • Liver Support Systems
    • Molecular Adsorbent Recirculating System
    • Bioartificial Liver Support
  • Cardiac Assist Devices
    • Intra-aortic Balloon Pump
    • Ventricular Assist Devices
    • Total Artificial Organs

By Modality

  • Portable/Transportable Devices
  • Bedside Devices
  • Implantable Devices

By Application

  • Respiratory Failure
  • Cardiac Failure
  • Liver Failure
  • Kidney Failure
  • Multi-Organ Failure

By Patient Type

  • Adult Patients
  • Pediatric Patients
  • Neonatal Patients

By End-User

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Intensive Care Units (ICUs)

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • The rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa

Competitive Landscape

The major global players in the integrated organ support therapies market include Emulate, Inc., Baxter International Inc., Fresenius Medical Care AG, Getinge AB, LivaNova, Inc., Asahi Kasei Corporation, ADVITOS GmbH, NIHON KOHDEN CORPORATION, Vapotherm, Fisher & Paykel Healthcare Limited and among others.

Key Developments

  • In August 2024, Talphera, Inc. declared that the NEPHRO CRRT study's first patient has been recruited. 166 individuals receiving continuous renal replacement therapy (CRRT) at up to 14 clinical locations across the US will be included in the NEPHRO CRRT registrational research. The mean post-filter activated clotting time for circuits injected with nafamostat versus placebo for the first 24 hours is the study's main outcome.
  • In April 2022, Baxter International Inc. released the U.S. Food and Drug Administration (FDA) 510(k) clearance 0f ST Set for use in continuous renal replacement therapy (CRRT). The ST Set is a disposable, extracorporeal (outside the body) circuit that comes pre-connected and may be used with the PrisMax or Prismaflex control units (monitors). It purifies blood through a semipermeable membrane.

Why Purchase the Report?

  • To visualize the global integrated organ support therapies market segmentation based on therapy type, modality, application, patient type, end-user and region and understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of the integrated organ support therapies market with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping is available in excel consisting of key products of all the major players.

The global integrated organ support therapies market report would provide approximately 78 tables, 77 figures and 179 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Therapy Type
  • 3.2. Snippet by Modality
  • 3.3. Snippet by Application
  • 3.4. Snippet by Patient Type
  • 3.5. Snippet by End-User
  • 3.6. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Prevalence of Chronic and Acute Organ Failure
      • 4.1.1.2. Technological Advancements in Organ Support Devices
    • 4.1.2. Restraints
      • 4.1.2.1. Risks and Complications Associated with Organ Support Therapies and Devices
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Patent Analysis
  • 5.5. Regulatory Analysis
  • 5.6. SWOT Analysis
  • 5.7. Unmet Needs

6. By Therapy Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 6.1.2. Market Attractiveness Index, By Therapy Type
  • 6.2. Extracorporeal Membrane Oxygenation (ECMO)*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 6.2.3. Veno-Venous (VV)
    • 6.2.4. Veno-Arterial (VA)
    • 6.2.5. Arterio-Venous (AV)
  • 6.3. Continuous Renal Replacement Therapy (CRRT)
    • 6.3.1. Continuous Venovenous Hemofiltration (CVVH)
    • 6.3.2. Continuous Venovenous Hemodialysis (CVVHD)
    • 6.3.3. Continuous Venovenous Hemodiafiltration (CVVHDF)
    • 6.3.4. Slow Continuous Ultrafiltration (SCUF)
  • 6.4. Extracorporeal CO2 Removal (ECCO2R)
  • 6.5. Liver Support Systems
    • 6.5.1. Molecular Adsorbent Recirculating System
    • 6.5.2. Bioartificial Liver Support
  • 6.6. Cardiac Assist Devices
    • 6.6.1. Intra-aortic Balloon Pump
    • 6.6.2. Ventricular Assist Devices
    • 6.6.3. Total Artificial Organs

7. By Modality

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 7.1.2. Market Attractiveness Index, By Modality
  • 7.2. Portable/Transportable Devices *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Bedside Devices
  • 7.4. Implantable Devices

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Respiratory Failure*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Cardiac Failure
  • 8.4. Liver Failure
  • 8.5. Kidney Failure
  • 8.6. Multi-Organ Failure

9. By Patient Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 9.1.2. Market Attractiveness Index, By Patient Type
  • 9.2. Adult Patients*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Pediatric Patients
  • 9.4. Neonatal Patients

10. By End-User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.1.2. Market Attractiveness Index, By End-User
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Specialty Clinics
  • 10.4. Ambulatory Surgical Centers
  • 10.5. Intensive Care Units (ICUs)

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.8.1. U.S.
      • 11.2.8.2. Canada
      • 11.2.8.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.8.1. Germany
      • 11.3.8.2. U.K.
      • 11.3.8.3. France
      • 11.3.8.4. Spain
      • 11.3.8.5. Italy
      • 11.3.8.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.8.1. Brazil
      • 11.4.8.2. Argentina
      • 11.4.8.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.8.1. China
      • 11.5.8.2. India
      • 11.5.8.3. Japan
      • 11.5.8.4. South Korea
      • 11.5.8.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Emulate, Inc.*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Baxter International Inc.
  • 13.3. Fresenius Medical Care AG
  • 13.4. Getinge AB
  • 13.5. LivaNova, Inc.
  • 13.6. Asahi Kasei Corporation
  • 13.7. ADVITOS GmbH
  • 13.8. NIHON KOHDEN CORPORATION
  • 13.9. Vapotherm
  • 13.10. Fisher & Paykel Healthcare Limited

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us